Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy

PURPOSE OF REVIEW: Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). In this review, we will focus on...

Descripción completa

Detalles Bibliográficos
Autores principales: Minczeles, N.S., Hofland, J., de Herder, W.W., Brabander, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Neuroendocrine Neoplasms (NS Reed, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960621/
https://www.ncbi.nlm.nih.gov/pubmed/33721105
http://dx.doi.org/10.1007/s11912-021-01037-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960621/
https://www.ncbi.nlm.nih.gov/pubmed/33721105
http://dx.doi.org/10.1007/s11912-021-01037-7

Ejemplares similares